IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

This paper is being submitted via EFS-Web on August 20, 2009

In the event that this Paper is late filed, and the necessary petition for extension of time is not filed concurrently herewith, please consider this as a Petition for the requisite extension of time, and to the extent not already paid, authorization to charge the extension fee to Account No. 06-1378. In addition, authorization is hereby given to charge any fees for which payment has not been submitted, or to credit any overpayments, to Account No. 06-1378.

Patentee : Hiroyuki KOIKE et al.

Patent No. : 5,288,726

Issued : February 22, 1994

Serial No. : 07/941,676

Filed : September 8, 1992

For : TETRAHYDROTHIENOPYRIDINE DERIVATIVES...

Docket No. : 920676/HG

Customer No.: 01933

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR 1.322

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

S I R :

It is respectfully requested that a Certificate of Correction, as per the attached Form PTO/SB/44, be granted. The error is a Patent Office printing error.

This request is to correct Column 73, line 15 (Claim 42, line 2), by replacing "o" with --or-- following "thrombosis," as per the attached Form PTO/SB/44.

With respect to said error, enclosed is a copy of page 162 of the specification, wherein in line 2 of Claim 45 (Claim 42 in the Letters Patent) "or" follows "thrombosis."

Favorable action on this Request for a Certificate of Correction is respectfully requested.

Respectfully submitted,



Frishauf, Holtz, Goodman
& Chick, P.C.
220 Fifth Avenue, 16th Fl.
New York, NY 10001-7708
Tel. Nos. (212) 319-4900
(212) 319-4551/Ext. 219
Fax No.: (212) 319-5101
E-Mail Address: BARTH@FHGC-LAW.COM

Richard S. Barth
Reg. No. 28,180

RSB/ddf

Encs.: (1) Form PTO/SB/44
(2) copy of page 162 of specification

PTO/SB/44 (09-07)
Approved for use through 08/31/2010. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 5,288,726

APPLICATION NO.: 07/941,676

ISSUE DATE : February 22, 1994

INVENTOR(S) : Hiroyuki KOIKE et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 73, line 15 (Claim 42, line 2): following "thrombosis" replace "o" with --or--.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Richard S. Barth, Esq.
Frishauf, Holtz, Goodman & Chick, P.C.220 Fifth Aye., New York, NY 10001-7708

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

carbonylbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and pharmaceutically acceptable salts thereof.

43. The compound of Claim 1, selected from the group consisting of 5-[α-(2-fluorocyclopropylcarbonyl-2-fluorobenzyl]-2-oxo-2,4,5,6,7,7a-hexahydrothieno[3,2-c]-pyridine and its tautomer and pharmaceutically acceptable salts thereof.

44. The compound of Claim 1, selected from the group consisting of 2-acetoxy-5-[α-(2-fluorocyclopropyl-carbonyl-2-fluorobenzyl]-4,5,6,7-tetrahydrothieno[3,2-c]-pyridine and pharmaceutically acceptable salts thereof.

45. A pharmaceutical composition for the treatment and prophylaxis of thrombosis or embolisms, comprising an effective amount of a blood platelet aggregation inhibitor in admixture with a pharmaceutically acceptable carrier or diluent, wherein said inhibitor is at least one compound of formula (I), or a tautomer or pharmaceutically acceptable salt thereof, as claimed in Claim 1.

46. The composition of Claim 45, wherein:

R^1 represents a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms, a halogen atom, a fluoroalkyl group having from 1 to 4 carbon atoms and at least one fluorine atom, a hydroxy group, an alkoxy group having from 1 to 4 carbon atoms, a fluoroalkoxy group having from 1 to 4 carbon atoms and at least one fluorine atom, an alkylthio group having from 1 to 4 carbon atoms, a fluoroalkylthio group having from 1 to 4 carbon atoms and at least one fluorine atom, an amino group, an alkanoyl group having from 1 to 5 carbon atoms, a fluoroalkanoyl group having from 2 to 5 carbon atoms and at least one fluorine atom, an alkoxycarbonyl group